A brand new UPMC report discovered that whereas most well being programs now provide precision drugs applications, many nonetheless face challenges scaling them resulting from reimbursement, information integration and affected person engagement points. Well being system leaders say the sphere’s future relies on embedding genomics into routine care, in addition to proving its medical and monetary worth.
The put up Precision Drugs’s Subsequent Hurdle Isn’t Science — It’s Execution appeared first on MedCity Information.
